BioClinica™, Inc., (NASDAQ: BIOC), a leading provider of clinical trial management services, today announced that it has signed a three-year, multi-million dollar agreement for enterprise-wide EDC technology and data management services with a global, multi-billion dollar division of a Top 10 pharmaceutical company. Designed for maximum efficiency and flexibility, BioClinica Express™ will support nearly 200 studies annually for this organization. Together the firms have developed a common data model based on CDISC standards that will facilitate rapid deployment and study closeout while supporting a challenging clinical environment.
The client chose BioClinica Express as part of a broad evaluation of all the leading solutions to achieve its goal of running paperless clinic studies. This agreement marks the second enterprise-level, full-service EDC agreement that BioClinica has announced this year. BioClinica announced a similar agreement for BioClinica Express and data management services with Cephalon in February.
“Our client analyzed a wide variety of commercial EDC vendor options, including open source software. They selected BioClinica for its technology, clinical domain expertise and its experience in handling high volumes of clinical data study builds and deployments,” said Stephen Boccardo, VP of Sales.
BioClinica Express is a comprehensive EDC solution that coordinates and organizes the collection and dissemination of clean data, adding speed and quality to every part of the clinical trial process. Express will be used for direct data entry and BioClinica’s full service data management staff will assure that all data is cleaned and processed in a timely manner.
“This client is already recognized as a worldwide leader in therapeutic research -- now they are blazing new paths in efficiency and speed. BioClinica will help this organization to implement standards that will deliver efficiency and eliminate variability, which are the true keys to success. Through our partnership, BioClinica will help to support their challenging clinical environment where many studies are designed and deployed within a single week,” said Peter Benton, President of the eClinical Division for BioClinica.
“We believe this selection demonstrates the value that BioClinica’s unique strategy brings to clinical research, especially at the company-wide level. We are proud to offer this best-in-class solution to support our clients as they continue to pioneer scientific research on a global scale,” said Mark Weinstein, CEO of BioClinica.
About BioClinica, Inc.
BioClinica, Inc. is a leading global provider of integrated, technology-enhanced clinical trial management services. BioClinica supports pharmaceutical and medical device innovation with imaging core lab, internet image transport, electronic data capture, interactive voice and web response, Microsoft Office-Smart clinical trial management and clinical supply chain design and optimization solutions. BioClinica services maximize efficiency and manageability throughout all phases of the clinical trial process. With more than 20 years of experience and over 2,000 successful trials to date, BioClinica has supported the clinical development of many new medicines from early phase trials through final approval. BioClinica operates state-of-the-art, regulatory-body-compliant imaging core labs on two continents, and supports worldwide eClinical and data management services from offices in the United States, Europe and Asia. For more information, please visit www.bioclinica.com.
Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the consummation and the successful integration of current and proposed acquisitions, the timing of projects due to the variability in size, scope and duration of projects, estimates and guidance made by management with respect to the Company’s financial results, backlog, critical accounting policies, regulatory delays, clinical study results which lead to reductions or cancellations of projects, and other factors, including general economic conditions and regulatory developments, not within the Company’s control.The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. You should review the Company’s filings, especially risk factors contained in the Form 10-K and the recent Form 10-Q.